WYE: in the pipeline

Wyeth has been in the pits for some time mostly due to the multiple lawsuits over it's diet drug, Fenfen. It has a new drug in the pipeline that breaks down the amyloid plack in the brain which is theorized to be causing the dreaded Alzheimers disease.It is in stage three trials and news should be out in the next two months to confirm data. If the data supports the hypothesis and patients stop regressing it will be approved by the FDA It is not a cure as such but arrests the stage at which the patient is at. Benefits would be most noticeable in patients diagnosed early on. This medication, if approved, will send Wyeth Labs well back into profit. The potential for this upside is estimated to be better than 50%. The science makes sense and I think it's a pretty safe bet.